IRIS
SANTARPIA, Mariacarmela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.041
EU - Europa 3.106
AS - Asia 2.718
SA - Sud America 1.224
AF - Africa 87
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 6
Totale 11.189
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.954
SG - Singapore 1.193
BR - Brasile 1.078
IE - Irlanda 671
CN - Cina 628
SE - Svezia 537
IT - Italia 405
RU - Federazione Russa 376
HK - Hong Kong 365
GB - Regno Unito 243
VN - Vietnam 233
PL - Polonia 212
DE - Germania 188
FI - Finlandia 147
UA - Ucraina 86
IN - India 61
FR - Francia 53
AR - Argentina 49
AT - Austria 48
CA - Canada 38
ID - Indonesia 38
MX - Messico 34
BD - Bangladesh 33
EC - Ecuador 30
ZA - Sudafrica 29
IQ - Iraq 28
ES - Italia 25
TR - Turchia 25
BE - Belgio 21
MA - Marocco 19
NL - Olanda 18
CO - Colombia 16
JP - Giappone 16
UZ - Uzbekistan 15
VE - Venezuela 12
PE - Perù 11
PY - Paraguay 11
AE - Emirati Arabi Uniti 10
CZ - Repubblica Ceca 10
CL - Cile 9
TN - Tunisia 9
AZ - Azerbaigian 8
KE - Kenya 8
EE - Estonia 7
GR - Grecia 7
KZ - Kazakistan 7
LT - Lituania 7
PA - Panama 7
AL - Albania 6
BG - Bulgaria 6
IL - Israele 6
PK - Pakistan 6
AU - Australia 5
CH - Svizzera 5
CI - Costa d'Avorio 5
DO - Repubblica Dominicana 5
EG - Egitto 5
KG - Kirghizistan 5
NP - Nepal 5
UY - Uruguay 5
BY - Bielorussia 4
DZ - Algeria 4
JO - Giordania 4
KR - Corea 4
OM - Oman 4
RS - Serbia 4
BO - Bolivia 3
IR - Iran 3
MD - Moldavia 3
SA - Arabia Saudita 3
SK - Slovacchia (Repubblica Slovacca) 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
AO - Angola 2
EU - Europa 2
GE - Georgia 2
KH - Cambogia 2
LK - Sri Lanka 2
LV - Lettonia 2
NO - Norvegia 2
RO - Romania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CG - Congo 1
DK - Danimarca 1
ET - Etiopia 1
GA - Gabon 1
GT - Guatemala 1
HR - Croazia 1
HU - Ungheria 1
IS - Islanda 1
JM - Giamaica 1
KW - Kuwait 1
LB - Libano 1
LU - Lussemburgo 1
MT - Malta 1
MW - Malawi 1
NG - Nigeria 1
Totale 11.178
Salva come PNG Salva come JPEG
Città #
Dublin 671
Singapore 579
Dallas 566
Ashburn 550
Chandler 422
Hong Kong 364
Nyköping 306
Beijing 257
Jacksonville 228
Warsaw 208
Messina 177
Lancaster 144
Los Angeles 142
Princeton 132
Medford 121
Moscow 111
Dearborn 98
New York 93
Cambridge 90
The Dalles 90
Des Moines 89
Ann Arbor 77
São Paulo 72
Ho Chi Minh City 71
Munich 70
Redondo Beach 58
Rio de Janeiro 46
Hanoi 43
Turku 43
Buffalo 40
Boardman 37
Wilmington 37
Vienna 35
Tianjin 33
Dong Ket 32
Shenyang 28
Jinan 27
Jakarta 26
San Mateo 26
Seattle 25
Rome 24
Brooklyn 22
Nuremberg 22
Pune 22
Brussels 21
Montreal 20
Frankfurt am Main 19
Johannesburg 18
Belo Horizonte 17
Denver 17
Düsseldorf 17
Atlanta 16
Curitiba 16
Houston 16
Milan 16
Tokyo 16
London 15
Porto Alegre 15
Boston 14
Brasília 14
Nanjing 14
Quito 14
Santa Clara 14
Tashkent 14
Salvador 13
Biên Hòa 12
Catania 12
Woodbridge 12
Zhengzhou 12
Bexley 11
Goiânia 11
Hebei 11
Helsinki 11
Lappeenranta 11
Orem 11
Poplar 11
San Francisco 11
Baghdad 10
Campinas 10
Ningbo 10
Ribeirão Preto 10
Stockholm 10
São José do Rio Preto 10
Thái Bình 10
Amsterdam 9
Da Nang 9
Guayaquil 9
Hyderabad 9
Manaus 9
Paternò 9
Redwood City 9
Sumaré 9
Aracaju 8
Baku 8
Haiphong 8
Juiz de Fora 8
Phoenix 8
Scarsdale 8
Taizhou 8
Ankara 7
Totale 7.031
Salva come PNG Salva come JPEG
Nome #
Amplification and overexpression of the PSMB5 gene contributes to bortezomib resistance in retreatment of patients with multiple myeloma. 170
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy 163
Bone and lymph node metastases from occult mammary carcinoma: a case report of carcinoma of unknown primary (CUP) Syndrome 161
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations 152
Liver dysfunction in hcv infected patients with CD20-Positive B-Cell Lymphoma undergoing rituximab combination chemotherapy 144
Applications of genomics in NSCLC 138
EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients. 138
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy 137
Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer 135
Alectinib: A selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer 132
Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC) 132
Liquid biopsy for lung cancer early detection 130
Early assessment of chemotherapy-related cardiovascular toxicity in patients with breast cancer 128
Endocrine toxicity of immune checkpoint inhibitors (anti-PD-1/PD-L1) in advanced cancer 125
Activation of viral defense signaling in cancer 116
Targeted drugs in small-cell lung cancer 112
Author Correction to: Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy 111
Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathway 111
5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer 109
One-third of an archivial series of papillary thyroid cancer (Years 2007-2015) has coexistent chronic lymphocytic thyroiditis, which is associated with a more favorable Tumor-node-metastasis staging 108
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases 107
Age-related genetic abnormalities: the Achilles’ heel for customizing therapy in elderly lung cancer patients 106
Retrospective analiysis of P-STAT6 expression as predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate 105
Advances in immunotherapy for treatment of lung cancer 105
Association between XPD 312 single nucleotide polymorphism (SNP) and clinical outcome in stage IIIA-B non-small-cell lung cancer (NSCLC) patients (P) < 59 years (Y) treated with chemotherapy followed by surgery 103
On the pharmacogenetics of non-small cell lung cancer treatment 100
Immunotherapeutic Advances for NSCLC 99
PIK3CA mutations in breast cancer: a potential marker 93
Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC) 92
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer 91
DNA repair and mitotic checkpoint genes as potential predictors of chemotherapy response in non-small-cell lung cancer. 90
Efficacy and toxicity of weekly Docetaxel as second/third line chemotherapy for advanced Non Small Cell lung cancer (NSCLC) 88
Myeloid-derived suppressor cells absolute counts in predicting durable response to R-CHOP in patients with follicular lymphoma. 85
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 85
How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009–2014 84
Co-activation of STAT3 and YES-associated protein 1 (YAP1) pathway in EGFR-mutant NSCLC 84
Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do 83
Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: Understanding transforming growth factor-beta role 83
Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer 83
Adaptive Resistance Mechanisms in EGFR Mutant NSCLC 83
Liquid biopsy in non-small cell lung cancer: a comparison between different methodologies to detect somatic mutations 83
From the bench to the bed: individualizing treatment in non-small-cell lungcancer 82
Polymorphisms in DNA repair genes modulate survival incisplatin/gemcitabine-treated non-small-cell lung cancer patients 82
Emerging drugs for non-small-cell lung cancer. 81
PIK3CA mutations and BRCA1 expression in breast cancer: potential biomarkers for chemoresistance 81
KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer 81
ADCs and TCE in SCLC Therapy: The Beginning of a New Era? 79
A friendly approach to pesonalized treatment in lung adenocarcinoma. REVISTA COLOMBIANA DE HEMATOLOGÍA Y ONCOLOGÍA 78
Usefulness of predictive tests for cancer treatment 76
Immune checkpoint inhibitors and neurotoxicity: a focus on diagnosis and management for a multidisciplinary approach 75
Feasibility of cell-free circulating tumor DNA testing for lung cancer 75
Beyond platinum treatment for NSCLC: what does the future hold? 75
Non-small-cell lung cancer signaling pathways, metabolism, and PD-1/PD-L1 antibodies 75
null 75
Retrospective analysis of P-STAT6 expression as a predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate 74
History of extensive disease small cell lung cancer treatment: Time to raise the bar? a review of the literature 73
Circulating biomarkers as predictors of response to immune checkpoint inhibitors in NSCLC: Are we on the right path? 72
Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. 72
Rare histotypes of epithelial biliary tract tumors: A literature review 72
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario 71
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? 71
Implications of XPD312 in stage IIIA-B NSCLC 69
Immunotherapy in NSCLC: A promising and revolutionary weapon 69
Targeting MET amplification in EGFR-mutant non-small-cell lung cancer 69
Melanoma: oncogenic drivers and the immune system 68
Personalized treatment of early-stage non-small-cell lung cancer: The challenging role of EGFR inhibitors 68
Radiation recall during cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma 68
Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints 68
'Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research' 67
How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013 67
PIK3CA mutations: a potential predictive marker in advanced breast cancer treated with antimicrotubule-based chemotherapy. 67
Polycythemia vera and essential thrombocytemia treated with IFN-ALPHA2a: Evidence of a significant clinical activity and molecular response. 67
Eribulin Mesylate for the Treatment of Metastatic Hormone-refractory and Triple-negative Breast Cancer: A Multi-institutional Real-world Report on Efficacy and Safety 67
PIK3CA mutations in breast cancer: A potential predictive marker 66
Other targeted drugs in melanoma 66
Predicting the outcome of chemotherapy for lung cancer. 65
A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma 64
Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive 64
Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database 63
36th European Congress of Pathology – Abstracts 63
Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System 62
TRANSLATIONAL RESEARCH IN GLIOBLASTOMA MULTIFORME: A REVIEW OF MOLECULAR CRITERIA FOR PATIENT SELECTION 62
EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung 62
Terra firma-forme dermatosis 62
Quanto sono utilizzati in Italia i farmaci biosimilari? Uno studio retrospettivo sull'uso degli agenti stimolanti l'eritropoiesi negli anni 2009-2013 62
Human endogenous retroviruses and cancer 62
Treatment of non-small-cell lung cancer and pharmacogenomics: where we are andwhere we are going 61
Novel mutations in the NFkB and NOTCH pathways 61
BRCA1 and anti-angiogenesis: new perspectives on the treatment of non-small-cell lung cancer 61
Second-line therapy of squamous non-small cell lung cancer: an evolving landscape 61
Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System 60
Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance 60
Comprehensive genomic profiling of combined small cell lung cancer 60
Enfortumab Vedotin in metastatic bladder cancer: a case report of durable clinical efficacy in a pretreated patient 59
null 59
Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine 58
Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma 57
KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer 57
Osimertinib and dihydroartemisinin: A novel drug combination targeting head and neck squamous cell carcinoma. 57
Mosaicism in von Hippel-Lindau disease: an event important to recognize 56
Totale 8.568
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.722
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.722
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021398 0 0 0 0 0 59 40 82 67 88 19 43
2021/2022796 6 37 32 31 22 14 39 30 8 94 188 295
2022/20231.804 153 144 65 142 100 179 47 76 837 11 39 11
2023/2024551 34 75 40 41 38 132 33 28 13 29 4 84
2024/20252.932 47 31 66 145 155 110 76 646 727 204 258 467
2025/20263.482 390 562 720 713 667 430 0 0 0 0 0 0
Totale 11.604